Impact Of Metabolic Response-Based Adaptive Radiotherapy On The High Dose Volume And Normal Tissue Structures In Human Papilloma Virus-Positive Oropharyngeal Squamous Cell Carcinoma: A Pilot In-Silico Study

Human Papilloma Virus positive oropharyngeal squamous cell carcinoma (HPV+OPSCC) is rising in incidence. Patients with good prognosis HPV+OPSCC have nearly double the survival of HPV negative OPSCC. Standard treatment for locally advanced HPV+OPSCC is 6 or 7 weeks of radiotherapy (RT) at a dose biologically equivalent to 70 Gray (Gy) +/- concurrent chemotherapy. Toxicity rates during and after RT are high including mucositis, xerostomia,...